Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial

Merck and Moderna announced that their personalized mRNA cancer vaccine, intismeran autogene, met its primary endpoint in a Phase 3 study. The trial marks the first late-stage success for the experimental program, which tailors the vaccine to each patient's tumor mutations. The companies did not disclose full efficacy data but said they plan to present results at an upcoming medical meeting.